Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants
Sponsor: Juro Sciences Inc.
Summary
This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.
Official title: A Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Transdermal Doses of SFG-02 in Japanese and White Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-09
Completion Date
2026-04
Last Updated
2025-09-11
Healthy Volunteers
Yes
Conditions
Interventions
SFG-02
Transdermal Formulation (SFG-02)
Placebo
Transdermal Formulation (Placebo)
Locations (1)
Sumida Hospital
Tokyo, Japan